BCL2 and B-cell chronic lymphocytic leukemia: We have synthesised a small molecule inhibitor against Bcl2, Disarib, which exhibited cytotoxicity in Bcl2 ‘high’ cancer cell lines and CLL patient primary cells [10,11].